Buzz Stock of the Day- Misonix (MSON)

There were more than 28,000 prostate cancer-related deaths in 2008.

Many of the current treatments including radiation and hormone therapies either result in a recurrence of the cancer, or have harsh side effects such as osteoporosis and anemia.

Minimally invasive treatments in late clinical trials are showing promise, however.

Our Buzz Stock of the Day — Misonix, Inc. (Nasdaq: MSON) — is developing a prostate cancer therapy based on High Intensity Focused Ultrasound (HIFU) technology. The company’s HIFU-based therapy is in Phase III clinical trials at a number of academic centers throughout the U.S.

In 1999, Misonix obtained a 20 percent equity position in Focus Surgery, a company leading the way in High Intensity Focused Ultrasound (HIFU) technology. Misonix manufactures the product for Focus Surgery. Misonix also markets the SB500 in the United Kingdom, Europe and Russia.

Treatment time using HIFU is usually 3-4 hours, and patients will more than likely be discharged the same day, or next day at the doctors discretion, according to Misonix’s Web site.

We like Misonix because the company makes money from its portfolio of ultrasonic medical devices that are being used in cosmetic surgery, neurosurgery, and laparoscopic surgery; is aggressively expanding its geographic footprint, and has a very promising pipeline.

For the three months ended December 31, Misonix reported net income of $194,000, or $0.03 per-share, compared with a net loss of $117,000 or $0.02 per-share. Revenue for the company’s second fiscal quarter increased 5.1 percent over the same period last year, largely due to sales growth for the company’s medical device products.

“Our medical device business made solid progress as we expanded our sales opportunities both domestically and internationally,” said Misonix CEO, Michael McManus in an earnings release.

The company has made continued strides to expand it sales and distribution network recently, and announced several agreements to enter new markets including Eastern Europe, Belgium and Luxenbourg, and Israel.

Misonix also recently strengthened its balance sheet by selling its Ultrasonic Laboratory non-core business for $3.5 million.

Tags: biotech, buzz stocks, small cap stocks, technology

This entry was posted on Monday, April 13th, 2009 at 7:22 pm by admin and is filed under Health Care Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.